nach oben

Drugs

Erschienen in:

01.02.2007 | Review Article

The Clinical Applications of Fluorouracil in Ophthalmic Practice

verfasst von: Lekha M. Abraham, Dinesh Selva, Robert Casson, Dr Igal Leibovitch

Erschienen in: Drugs | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Fluorouracil (5-fluorouracil, 5-FU) is a pyrimidine analogue that was originally known for its widespread use as an anticancer drug. The ability of 5-FU to reduce fibroblastic proliferation and subsequent scarring has made it an important adjunct in ocular and periorbital surgeries. It is used in primary glaucoma filtering surgeries and in reviving failing filtering blebs, in dacryocystorhinostomy, pterygium surgery, and in vitreoretinal surgery to prevent proliferative vitreoretinopathy. In addition, 5-FU is also gaining recognition in the treatment and surgical management of ocular surface malignancies like ocular surface squamous neoplasia; however, the specific action of the drug on highly proliferating cells limits its use in primary acquired melanosis of the conjunctiva. When applied topically, this drug has a low rate of sight-threatening adverse effects, is inexpensive, and is easy to administer, making it an important tool in enhancing the success rate in ophthalmic surgery and in reducing the recurrence of ocular surface neoplasia.

The use of trade names is for product identification purposes only and does not imply endorsement.

Dushinski R, Pleven E, Heidelberger C. The synthesis of 5 fluoro pyrimidines. J Am Chem Soc 1957; 79: 4559–60CrossRef

Milano G, Ferrero J-M, Francois E. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer 2004; 91: 613–7PubMed

Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem-Anticancer Agents 2002; 2: 267–310PubMedCrossRef

Kubota T. 5-Fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol. 2003; 8: 127–31PubMedCrossRef

Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents: pyrimidine analogs. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s The pharmacological basis of therapeutics, 9th ed. New York: McGraw Hill,1996: 1247–51

Heimer R, Sartorelli AC. Reductions in gamma globulin mRNA levels restricted to the cytoplasm of 5-flurouridine treated K-562 human erythroleukemia cells. Cancer Commun 1990; 2: 45–3PubMed

Gordon SR, Climie M, Hitt AL. 5-Fluorouracil interferes with actin organization, stress fibre formation and cell migration in corneal endothelial cells during wound repair along the natural basement membrane. Cell Motil Cytoskeleton 2005; 62: 244–58PubMedCrossRef

Khaw PT, Ward S, Porter A, et al. The long term effects of 5-fluorouracil and sodium butyrate on human tenon’s fibroblasts. Invest Ophthalmol Vis Sci 1992; 33: 2043–52PubMed

Ashktorab H, Dawkins FW. Mohamed R, et al. Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. Dig Dis Sci 2005; 50: 1025–32

10.

Ophir A. Effects of 5-fluorouracil on proliferating fibroblasts in vivo. Exp Eye Res 1991; 53: 799–803PubMedCrossRef

11.

Khaw FT, Sherwood MB, Mackay SLD. Five minute treatments with fluorouracil, floxuridine and mitomycin have long term effects on human Tenon’s capsule fibroblasts. Arch Ophthalmol 1992; 110: 1150–4PubMedCrossRef

12.

Occleston NL, Alexander RA, Mazure A, et al. Effect of single exposures to antiproliferative agents on ocular fibroblast mediated collagen contraction. Invest Ophthalmol Vis Sci 1994; 35: 3681–90PubMed

13.

Smith S, D’Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Ophthalmol 1993; 116: 673–83

14.

Blumenkranz MS, Claflin A, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 1984; 102: 598–604PubMedCrossRef

15.

Rootman J, Tisdall J, Gadauskas G, et al. Intraocular penetration of subconjunctivally administered ¹⁴C-fluorouracil in rabbits. Arch Ophthalmol 1979; 97: 2375–8PubMedCrossRef

16.

Fantes FE, Heuer DK, Parrish RK III, et al. Topical fluorouracil: pharmacokinetics in normal rabbit eyes. Arch Ophthalmol 1985; 103: 953–5PubMedCrossRef

17.

Simmons ST, Sherwood MB, Nichols DA, et al. Pharmacokinetics of a 5-fluorouracil liposomal delivery system. Br J Ophthalmol 1988; 72: 688–91PubMedCrossRef

18.

Merriman MB, Mora JS, Beaumont BW, et al. Effects of varying 5-fluorouracil exposure duration on Tenon’s capsule fibroblasts. Clin Exp Ophthalmol 2001; 29: 248–52CrossRef

19.

Jams G, Blumenkranz M, Hernandez E, et al. Clearance of intravitreal fluorouracil: normal and aphakic vitrectomized eyes. Ophthalmology 1985; 92: 91–6

20.

Blumenkranz MS, Ophir A, Claflin AJ, et al. Fluorouracil for treatment of massive pre retinal proliferation. Am J Ophthalmol 1982; 94: 458–67PubMed

21.

Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003; 48: 314–46PubMedCrossRef

22.

Costa PV, Spaeth GL, Eiferman RA, et al. Wound healing modulation in glaucoma filtering surgery. Ophthalmic surgery 1993; 24: 152–70PubMed

23.

Peng TK, Migdal CS. Current techniques in wound healing modulation in glaucoma surgery. Curr Opin Ophthalmol 1996; 7: 24–33

24.

Weinreb RN. Adjusting the dose of 5-fluorouracil after filtering surgery to minimize side effects. Ophthalmology 1987; 94: 564–70PubMed

25.

Heuer DK, Parrish RK, Gressel MG. 5-Fluorouracil and glaucoma filtering surgery II: a pilot study. Ophthalmology 1984; 94: 1071–8

26.

Spaeth GI, Mutlukan E. The use of antimetabolites with trabeculectomy: a critical appraisal. J Glaucoma 2001; 10: 145–51PubMedCrossRef

27.

Heuer DK, Parrish RK, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery III: intermediate follow up of a pilot study. Ophthalmology 1986; 93: 1537–46PubMed

28.

Ruderman J, Welch D, Smith M, et al. A randomized trial of 5 fluorouracil and filtration surgery. Am J Ophthalmol 1987; 104: 218–24PubMed

29.

Araie M, Shoji N, Shirato S, et al. Postoperative subconjunctival 5-fluorouracil injections and success probability of trabeculectomy in Japanese: results of 5-year follow-up. Jpn J Ophthalmol 1992; 36: 158–68PubMed

30.

Ophir A, Ticho U. A randomized study of trabeculectomy and subconjunctival administration of fluorouracil in primary glaucomas. Arch Ophthalmol 1992; 110: 1072–5PubMedCrossRef

31.

Goldenfeld M, Krupin T, Ruderman JM, et al. 5-Fluorouracil in initial trabeculectomy: a prospective, randomized, multicenter study. Ophthalmology 1994; 101: 1024–9PubMed

32.

The Fluorouracil Filtering Surgery Study Group. Five year follow up of the fluorouracil surgery study. Am J Ophthalmol 1996; 121: 349–66

33.

Chaudry IA, Pasha MA, O’Connor DJ, et al. Randomized, controlled study of low-dose 5-fluorouracil in primary trabeculectomy. Am J Ophthalmol 2000; 130: 700–3CrossRef

34.

Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow up. Ophthalmology 2000; 107: 1184–90PubMedCrossRef

35.

Akarsu C, Onol M, Hasareisoglu B. Post operative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up. Clin Experiment Ophthalmol 2003; 31: 199–205PubMedCrossRef

36.

Anand N, Sahni K, Menage MJ. Modification of trabeculectomy with single-dose intraoperative 5-fluorouracil application. Acta Ophthalmol Scand 1998; 76: 83–9PubMedCrossRef

37.

Mielke C, Dawda VK, Anand N. Intraoperative 5-fluorouracil application during primary trabeculectomy in Nigeria: a comparative study. Eye 2003; 17: 829–34PubMedCrossRef

38.

Bell RW, Habib NE, O’Brien C. Long-term results and complications after trabeculectomy with a single per-operative application of 5-fluorouracil. Eye 1997; 11: 663–71PubMedCrossRef

39.

Mora JS, Nguyen N, Iwach AG, et al. Trabeculectomy with intraoperative sponge 5-fluorouracil. Ophthalmology 1996; 103: 963–70PubMed

40.

Sidoti PA, Choi JC, Morinelli EN, et al. Trabeculectomy with intraoperative 5-fluorouracil. Ophthalmic Surg Lasers 1998; 29: 552–61PubMed

41.

Wudunn D, Cantor LB, Palanca-Capistrano AM, et al. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. Am J Ophthalmol 2002; 134: 521–7PubMedCrossRef

42.

Singh K, Mehta K, Shaik NM, et al. Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil: prospective randomized clinical trial. Ophthalmology 2000; 107: 2305–9PubMedCrossRef

43.

Suzuki R, Dickens CJ, Iwach AG, et al. Long-term follow-up of initially successful trabeculectomy with 5-fluorouracil injections. Ophthalmology 2002; 109: 1921–4PubMedCrossRef

44.

Wolner B, Liebmann JM, Sassani JW, et al. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology 1991; 98: 1053–60PubMed

45.

Siriwardena D, Kotecha A, Minassian D, et al. Anterior chamber flare after trabeculectomy and after phacoemulsification. Br J Ophthalmol 2000; 84: 1056–7PubMedCrossRef

46.

Lochhead J, Casson RJ, Salmon JF. Long term effect on intraocular pressure of phacotrabeculectomy compared to trabeculectomy. Br J Ophthalmol 2003; 87: 850–2PubMedCrossRef

47.

Fraser S, Phelan PS. Cataract surgery and IOP. Br J Ophthalmol 2005; 89: 1228PubMedCrossRef

48.

Hennis HL, Stewart WB. The use of 5 fluorouracil in patients following combined trabeculectomy and cataract extraction. Ophthalmic Surg 1991; 22: 451–4PubMed

49.

O’Grady JM, Juzych MS, Shin DH, et al. Trabeculectomy, phacoemulsification, and posterior chamber lens implantation with and without 5-fluorouracil. Am J Ophthalmol 1993; 116: 594–595 99PubMed

50.

Gandolfi SA, Vecchi M. 5-Fluorouracil in combined trabeculectomy and clear-cornea phacoemulsification with posterior chamber intraocular lens implantation: a one-year randomized, controlled clinical trial. Ophthalmology 1997; 104: 181–6PubMed

51.

Ren J, Shin DH, O’Grady JM, et al. Long-term outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol 1998; 236: 501–6PubMedCrossRef

52.

Budenz DL, Pyfer M, Singh K, et al. Comparison of phacotrabeculectomy with 5-fluorouracil, mitomycin-C, and without antifibrotic agents. Ophthalmic Surg Lasers 1999; 30: 367–74PubMed

53.

Donoso R, Rodriguez A. Combined versus sequential phacotrabeculectomy with intraoperative 5-fluorouracil. J Cataract Refract Surg 2000; 26: 71–4PubMedCrossRef

54.

Singh RP, Goldberg I, Mohsin M. The efficacy and safety of intraoperative and/or postoperative 5-fluorouracil in trabeculectomy and phacotrabeculectomy. Clin Experiment Ophthalmol 2001; 29: 296–302PubMedCrossRef

55.

Zalish M, Leiba H, Oliver M. Subconjunctival injection of 5-fluorouracil following trabeculectomy for congenital and infantile glaucoma. Ophthalmic Surg 1992; 23: 203–5PubMed

56.

Snir M, Luskey M, Shalev B, et al. Mitomycin C and 5-fluorouracil antimetabolite therapy for pediatric glaucoma filtration surgery. Ophthalmic Surg Lasers 2000; 31: 31–7PubMed

57.

Cantor L, Burgoyne J, Sanders S, et al. The effect of mitomycin C on molteno implant surgery. J Glaucoma 1998; 7: 240–6PubMedCrossRef

58.

Trible JR, Brown DB. Occlusive ligature and standardized fenestration of a Baerveldt tube with and without antimetabolites for early postoperative intraocular pressure control. Ophthalmology 1998; 105: 2243–50PubMedCrossRef

59.

Jacob JT, Lacour OJ, Burgoyne CF. Slow release of the antimetabolite 5-fluorouracil (5-FU) from modified Baerveldt glaucoma drains to prolong drain function. Biomaterials 2001; 22: 3329–35PubMedCrossRef

60.

Broadway DC, Bloom PA, Bunce C, et al. Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil: survival analysis. Ophthalmology 2004; 111: 665–73PubMedCrossRef

61.

Allen LE, Manuchehri K, Corridan PG. The treatment of encapsulated trabeculectomy blebs in an out-patient setting using a needling technique and subconjunctival 5-fluorouracil injection. Eye 1998; 12: 119–23PubMedCrossRef

62.

Shin DH, Juzych MS, Khatana AK, et al. Needling revision of failed filtering blebs with adjunctive 5-fluorouracil. Ophthalmic Surg 1993; 24: 242–8PubMed

63.

Ophir A, Porges Y. Needling with intra bleb 5-fluorouracil for intractable neovascular glaucoma. Ophthalmic Surg Lasers 2000; 31: 38–42PubMed

64.

Dion E. The treatment of pterygium. Ophthalmic Surg 1977; 8: 12–30

65.

Lewallen S. A randomized controlled trial of conjunctival autografting for pterygium in the tropics. Ophthalmology 1989; 96: 1612–4PubMed

66.

Essex RW, Snibson GR, Daniell M, et al. Amniotic membrane grafting in the surgical management of primary pterygium. Clin Exp Ophthalmol 2004; 32: 501–4CrossRef

67.

Brenner DJAU, Merriam GR. Postoperative radiation for pterygium: guidelines for optimal treatment. Int J Radiat Oncol Biol Phys 1994; 30: 721–5PubMedCrossRef

68.

Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology 1992; 99: 1647–54PubMed

69.

Hsiao CH, Chen JJ, Huang SC, et al. Intrascleral dissemination of infectious scleritis following pterygium excision. Br J Ophthalmol 1998; 82: 29–34PubMedCrossRef

70.

Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea 1996; 15: 537–40PubMedCrossRef

71.

Maldonado MJ, Cano-Parra J, Navea-Tejerina A, et al. Inefficacy of low dose intraoperative fluorouracil in the treatment of primary pterygium. Arch Ophthalmol 1995; 113: 1356–7PubMedCrossRef

72.

Bekibele CO, Baiyeroju AM, Ajayi BGK. 5-Fluorouracil vs. beta-radiation in the prevention of pterygium recurrence. Int J Clin Pract 2004; 58: 920–3

73.

Pikkel J, Porges Y, Ophir A. Halting pterygium recurrence by postoperative 5 fluorouracil. Cornea 2001; 20: 168–71PubMedCrossRef

74.

Akarsu C, Taner P, Ergin A. 5-Fluorouracil as chemoadjuvant for primary pterygium surgery: preliminary report. Cornea 2003; 22: 522–6PubMedCrossRef

75.

Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology 2006; 113: 1102–9PubMedCrossRef

76.

Toti A. Nuovo metodo conservatore di cura radicale delie suporazioni chroniche del sacco lacrimale. Clin Mod Firenze 1904; 10: 385–9

77.

Iliff CE. A simplified dacryocystorhinostomy. Arch Ophthalmol 1971; 85: 586–91PubMedCrossRef

78.

Pico G. A modified technique of external dacryocystorhinostomy. Am J Ophthalmol 1971; 72: 679–89PubMed

79.

Bakri K, Jones NS, Downes R, et al. Intraoperative fluorouracil in endonasal laser dacryocystorhinostomy. Arch Otolaryngol Head Neck Surg 2003; 129: 233–5PubMedCrossRef

80.

Bakri SJ, Carney AS, Downes RN, et al. Endonasal laser assisted dacryocystorhinostomy: a review. Hosp Med 1998; 59: 210–5PubMed

81.

Sadiq SA, Ohrlich S, Jones NS, et al. Endonasal laser dacryocystorhinostomy-medium term results. Br J Ophthalmol 1997; 81: 1089–92PubMedCrossRef

82.

Boush GA, Lemke BN, Dortzbach RK. Results of endonasal laser assisted dacryocystorhinostomy. Ophthalmology 1994; 101: 955–9PubMed

83.

Tarbet KJ, Custer PL. External dacryocystorhinostomy: surgical success, patient satisfaction, and economic cost. Ophthalmology 1995; 102: 1065–70PubMed

84.

Walland MJ, Rose GE. Factors affecting the success rate of open lacrimal surgery. Br J Ophthalmol 1994; 78: 888–91PubMedCrossRef

85.

Yalaz M, Firinciogullari E, Zeren H. Use of mitomycin C and 5-fluorouracil in external dacryocystorhinostomy. Orbit 1999; 18: 239–45PubMedCrossRef

86.

Watts P, Ram AR, Nair R, et al. Comparison of external dacryocystorhinostomy and 5-fluorouracil augmented endonasal laser dacryocystorhinostomy: a retrospective review. Indian J Ophthalmol 2001; 49: 169–72PubMed

87.

Machemer R. Proliferative vitreoretinopathy: a personal account of its pathogenesis and treatment. Invest Ophthalmol Vis Sci 1988; 29: 1771–83PubMed

88.

The Silicone Study Group. Proliferative vitreoretinopathy. Am J Ophthalmol. 1985; 99: 593–5

89.

Chandler DB, Rozakis G, Dejuan E, et al. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 1985; 99: 686–90PubMed

90.

Khawly JA, Saloupis P, Hatchell DL, et al. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1991; 229: 464–7PubMedCrossRef

91.

Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained release triamcinolone and 5-flourouracil in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998; 116: 69–77PubMed

92.

Kon CH, Accleston NL, Foss A, et al. Effects of single, short term exposures of human retinal pigment epithelial cells to thiotepa and 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy. Br J Ophthalmol 1998; 82: 554–60PubMedCrossRef

93.

Blumenkranz M, Hernandez E, Ophir A, et al. 5-Fluorouracil: new applications of complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91: 122–30PubMed

94.

Blankenship GW. Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol 1989; 227: 565–8PubMedCrossRef

95.

Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized double blind clinical trial. Ophthalmology 2001; 108: 1179–83PubMedCrossRef

96.

Charteris GD, Aylward GW, Wong D, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004; 111: 2240–5PubMedCrossRef

97.

Cardillo JA, Farah ME, Mitre J, et al. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post traumatic proliferative vitreoretinopathy. Br J Ophthalmol 2004; 88: 1201–5PubMedCrossRef

98.

Majumdar PA, Epstein RJ. Antimetabolites in ocular surface neoplasia. Curr Opin Ophthalmol 1998; 9: 35–9CrossRef

99.

Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol 1995; 39: 429–50PubMedCrossRef

100.

Basti S, Macsai MS. Ocular surface neoplasia: a review. Cornea 2003; 22: 687–704PubMedCrossRef

101.

de Keizer RJW, de Wolff-Rouendall D, van Delft JL. Topical application of 5-fluorouracil in premalignant lesions of cornea conjunctiva and eyelid. Doc Ophthalmol 1986; 64: 31–42PubMedCrossRef

102.

Yeatts RP, Ford JG, Stanton CA, et al. Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea. Ophthalmology 1995; 102: 1338–44PubMed

103.

Midena E, Boccato P, Angeli CD. Conjunctival squamous cell carcinoma treated with topical 5-fluorouracil. Arch Ophthalmol 1997; 115: 1600–1PubMedCrossRef

104.

Midena E, Angeli CD, Valenti M, et al. Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol 2000; 84: 268–72PubMedCrossRef

105.

Yeatts RP, Engelbrecht NE, Curry CD, et al. 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 2000; 107: 2190–5PubMedCrossRef

106.

Yamamoto N, Ohmura T, Suzuki H, et al. Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C. Ophthalmology 2002; 109: 249–52PubMedCrossRef

107.

Lin SM, Ferrucci S. Primary acquired melanosis of the conjunctiva. Optometry 2006; 77: 223–8PubMedCrossRef

108.

Stone DU, Butt AL, Chodosh J. Ocular surface squamous neoplasia: a standard of care survey. Cornea 2005; 24: 297–300PubMedCrossRef

109.

Shapiro MS, Thoft RA, Friend J, et al. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci 1985; 26: 580–3PubMed

110.

Knapp A, Heuer DK, Stern GA, et al. Serious corneal complications of glaucoma filtering surgery with post operative 5-fluorouracil. Am J Ophthalmol 1987; 103: 183–7PubMed

111.

Traverso CE, Facino M, Murialdo U, et al. Decrease corneal complications after no reflux, low dose 5 fluorouracil subconjunctival injection following trabeculectomy. Int Ophthalmol 1994; 18: 247–50PubMedCrossRef

112.

Mochizuki K, Jikiihara S, Ando Y, et al. Incidence of delayed onset infection after trabeculectomy with adjunctive mitomycin C or 5-fluorouracil treatment. Br J Ophthalmol 1997; 81: 877–83PubMedCrossRef

113.

Susanna R, Takahashi W, Nicolele M. Late bleb leakage after trabeculectomy with 5-fluorouracil or mitomycin C. Can J Ophthalmol 1996; 31: 296–300PubMed

114.

Solomon A, Ticho U, Frucht-Pery J. Late-onset, bleb-associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. J Ocul Pharmacol Ther 1999; 15: 283–93PubMedCrossRef

115.

Song A, Scott IU, Flynn HW, et al. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology 2002; 109: 985–91PubMedCrossRef

116.

Ticho U, Ophir A. Late complications after glaucoma filtering surgery with adjunctive 5-fluorouracil. Am J Ophthalmol 1993; 115: 506–10PubMed

117.

Wells AP, Cordiero MF, Bunce C, et al. Cystic bleb formation and related complications in limbus-versus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C. Ophthalmology 2003; 110: 2192–7PubMedCrossRef

118.

Abraham LM, Selva D, Casson RJ, et al. Mitomycin: clinical applications in ophthalmic practice. Drugs 2006; 66: 321–40PubMedCrossRef

119.

Lamping KA, Belkin JK. 5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995; 102: 70–5PubMed

120.

Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil vs. mitomycin C. Am J Ophthalmol 1997; 123: 48–53

121.

Vijaya L, Mukhesh BN, Shantha B, et al. Comparison of low dose intraoperative mitomycin C vs. 5-fluorouracil in primary glaucoma surgery: a pilot study. Ophthalmic Surg Lasers 2000; 31: 24–30

122.

Smith MF. Doyle JW, Nguyen QH, et al. Results of intraoperative 5-fluorouracil or lower dose mitomycin C on initial trabeculectomy surgery. J Glaucoma 1997; 6: 104–10PubMed

123.

Katz GJ, Higginbotham GJ, Lichter PR, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery: extended follow-up. Ophthalmology 1995; 102: 1263–9PubMed

124.

Membrey WL, Poinooswamy DP, Bunce C, et al. Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: intraocular pressure control and complications. Br J Ophthalmol 2000; 84: 586–90PubMedCrossRef

125.

Andreo LK, Uyemura MJ, Enzenaur RW. 5-Fluorouracil reduces scarring after strabismus surgery. J Pediatr Ophthalmol Strabismus 1997; 34: 107–10PubMed

126.

Esme A, Yidirim C, Tatlipinar S, et al. Effects of intraoperative sponge mitomycin C and 5-fluorouracil on scar formation following strabismus surgery in rabbits. Strabismus 2004; 12: 141–8PubMedCrossRef

127.

Hwang JM. Chang BL. Combined effect of polytetrafluoroethylene and 5-fluorouracil on delayed adjustable strabismus surgery. J Pediatr Ophthalmol Strabismus 2000; 37: 163–7

128.

Hwang JM. Chang BL. Combined effect of Interceed and 5-fluorouracil on delayed adjustable strabismus surgery. Br J Ophthalmol 1999; 83: 788–91

129.

Ismail MM, Alio JL, Ruiz Moreno JM. Prevention of secondary cataract by antimitotic drugs: experimental study. Ophthalmic Res 1996; 28: 64–9PubMedCrossRef

130.

Fernandez V, Fragoso MA, Billotte C, et al. Efficacy of various drugs in the prevention of posterior capsule opacification: experimental study of rabbit eyes. J Cataract Refract Surg 2004; 30: 2598–605PubMedCrossRef

Titel: The Clinical Applications of Fluorouracil in Ophthalmic Practice
verfasst von: Lekha M. Abraham
Dinesh Selva
Robert Casson
Dr Igal Leibovitch
Publikationsdatum: 01.02.2007
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 2/2007
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200767020-00005

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Clinical Applications of Fluorouracil in Ophthalmic Practice

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder

Optimising Antimicrobial Therapy in Diabetic Foot Infections

Treatment Approaches for Painful Bladder Syndrome/Interstitial Cystitis

Voriconazole

Guidelines and Recommendations for the Management of Anaemia in Patients with Lymphoid Malignancies

Selegiline Transdermal System In the Treatment of Major Depressive Disorder